HLBpep has begun expanding its global peptide contract development and manufacturing organization (CDMO) business.


At the business agreement ceremony between HLBpep and the Japanese peptide specialty company PeptiGrowth held on the 18th at the HLBpep headquarters in Gwangju Metropolitan City, HLBpep CEO Shim Kyungjae (second from the left) and PeptiGrowth officials are taking a commemorative photo. HLBpep

At the business agreement ceremony between HLBpep and the Japanese peptide specialty company PeptiGrowth held on the 18th at the HLBpep headquarters in Gwangju Metropolitan City, HLBpep CEO Shim Kyungjae (second from the left) and PeptiGrowth officials are taking a commemorative photo. HLBpep

View original image

On the 19th, HLBpep announced that it had signed a memorandum of understanding (MOU) with the Japanese peptide specialist company PeptiGrowth for the development and manufacturing of advanced functional peptides.


The two companies have agreed to collaborate on several areas: the development of next-generation synthetic peptide growth factors and cytokines; the establishment of advanced peptide manufacturing processes; cooperation in building a GMP-based production system; and expanding global supply capabilities.


PeptiGrowth is a company specializing in the development of synthetic peptides that can replace conventional growth factors. It is gaining attention in the regenerative medicine market by developing synthetic peptide solutions designed to overcome the limitations of traditional recombinant protein-based growth factors.


This collaboration is particularly expected to serve as an opportunity for HLBpep to expand its global functional peptide CDMO business.


HLBpep plans to support PeptiGrowth in manufacturing functional peptides, leveraging its expertise in peptide synthesis and purification technologies. HLBpep possesses strong capabilities in optimizing processes and scaling up the manufacturing of structurally complex and technically challenging peptides.



An HLBpep official stated, "As the regenerative medicine and cell therapy industries continue to grow, demand for high-functional peptides is surging. This MOU will be a significant opportunity to expand HLBpep's precision peptide manufacturing technology into the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing